Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ROVI.MC
- Price
- 55.05
- Stock movement down
- -0.05 (-0.09%)
- Company name
- Laboratorios Farmaceuticos ROVI
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 2.82B
- Ent værdi
- 3.15B
- Pris/omsætning
- 3.62
- Pris/bog
- 5.83
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- 198.96%
- Efterfølgende P/E
- 19.02
- Fremtidig P/E
- 16.36
- PEG
- -
- EPS-vekst
- 59.01%
- 1 års afkast
- -33.67%
- 3 års afkast
- -2.26%
- 5 års afkast
- 10.98%
- 10 års afkast
- 15.01%
Senest opdateret: 2025-06-22
UDBYTTE
ROVI.MC betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 19.02 |
| Pris til OCF | 31.13 |
| Pris til FCF | 80.99 |
| Pris til EBITDA | 12.93 |
| EV i forhold til EBITDA | 14.45 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 3.62 |
| Pris til egenkapital | 5.83 |
| EV i forhold til salg | 4.04 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 51.15M |
| EPS (TTM) | 2.77 |
| FCF pr. aktie (TTM) | 0.65 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 778.00M |
| Bruttofortjeneste (TTM) | 470.81M |
| Driftsindkomst (TTM) | 191.53M |
| Nettoindkomst (TTM) | 148.03M |
| EPS (TTM) | 2.77 |
| EPS (1 år frem) | 3.36 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 60.52% |
| Driftsmargin (TTM) | 24.62% |
| Fortjenstmargin (TTM) | 19.03% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 44.58M |
| Nettotilgodehavender | 120.83M |
| Omsætningsaktiver i alt | 540.78M |
| Goodwill | -5.94M |
| Immaterielle aktiver | 27.09M |
| Ejendomme, anlæg og udstyr | 500.08M |
| Sum aktiver | 857.33M |
| Kreditor | 80.88M |
| Kortfristet/nuværende langsigtet gæld | 121.16M |
| Summen af kortfristede forpligtelser | 272.45M |
| Sum gæld | 374.56M |
| Aktionærernes egenkapital | 482.76M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 90.46M |
| Investeringsudgifter (TTM) | 55.69M |
| Fri pengestrøm (TTM) | 34.77M |
| Udbetalt udbytte (TTM) | 69.18M |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 30.66% |
| Afkast af aktiver | 17.27% |
| Afkast af investeret kapital | 29.27% |
| Kontant afkast af investeret kapital | 6.87% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 55.10 |
| Daglig høj | 55.50 |
| Daglig lav | 54.95 |
| Daglig volumen | 251K |
| Højeste gennem alle tider | 91.50 |
| 1 års analytiker estimat | 92.01 |
| Beta | 0.48 |
| EPS (TTM) | 2.77 |
| Udbytte pr. aktie | - |
| Ex-div dato | 14 Jul 2025 |
| Næste dato for resultatpræsentation | 29 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ROVI.MC | S&P500 | |
| Nuværende prisfald fra top notering | -39.84% | -3.04% |
| Højeste prisfald | -67.18% | -56.47% |
| Højeste efterår dato | 6 Mar 2009 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -25.38% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 28 days | 12 days |
| Maks. tid til nyt højdepunkt | 1773 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
2.82B
Markedsværdi kategori
Mid-cap
Beskrivelse
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Personale
2111
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Spain
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
As European markets show mixed performance, with the pan-European STOXX Europe 600 Index remaining relatively flat and major indices like France's CAC 40 and Italy's FTSE MIB posting modest gains, inv...
11. juli 2025
As the pan-European STOXX Europe 600 Index remains relatively flat and major stock indexes show mixed returns, investors are keenly observing economic indicators such as inflation rates and labor mark...
10. juli 2025
As global markets continue to experience robust performance, with major U.S. indices like the S&P 500 and Nasdaq Composite reaching record highs, investors are increasingly on the lookout for opportun...
10. juli 2025
As the European markets experience mixed returns, with the STOXX Europe 600 Index remaining roughly flat and major indices showing varied performance, investors are keeping a close eye on economic ind...
10. juli 2025
As the pan-European STOXX Europe 600 Index remains relatively flat and major stock indexes exhibit mixed returns, investors are keenly observing economic indicators such as inflation rates and labor m...
7. juli 2025
As the pan-European STOXX Europe 600 Index remains relatively flat and major stock indexes show mixed returns, investors are keeping a close eye on economic indicators such as eurozone inflation reach...
4. juli 2025
As the European markets show signs of resilience, with the STOXX Europe 600 Index climbing 1.32% amid easing geopolitical tensions and promises of economic stimulus, investors are keenly assessing opp...
3. juli 2025
As global markets recently celebrated record highs, driven by easing geopolitical tensions and positive trade developments, investors are keenly observing opportunities amidst fluctuating economic ind...
2. juli 2025
As European markets face challenges with the pan-European STOXX Europe 600 Index ending 1.54% lower amid concerns over Middle East tensions, investors are keenly observing opportunities in stocks that...
26. juni 2025
As the European market navigates through a period of heightened global uncertainty, with indices such as the STOXX Europe 600 reflecting concerns over geopolitical tensions, investors are increasingly...
26. juni 2025
Næste side